Stock Events

Stock Events

Quince Therapeutics 

$18.88
64
+$0.21+1.12% Friday 20:00
-$0.03-0.17%Friday 23:35After hours

Statistics

Day High
18.86
Day Low
18.76
52W High
910
52W Low
15.1
Volume
1,679
Avg. Volume
-
Mkt Cap
18.46M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

11AugExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Next
-26
8.29
42.58
76.88
Expected EPS
-25.4
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-83.98MNet Income

Analyst Ratings

4.00Average Price Target
The highest estimate is 4.00.
From 4 ratings within the last 6 months. This is not an investment recommendation.
Buy
50%
Hold
50%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow QNCX. It's not an investment recommendation.
Microsoft
9
MSFT
Apple
8
AAPL
Tesla
8
TSLA
Amazon
8
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Sangamo Therapeutics
SGMO
Mkt Cap30.66M
Sangamo Therapeutics, Inc. competes in the development of genomic therapies addressing a range of genetic disorders, similar to Quince Therapeutics' focus on regenerative medicines.
CRISPR Therapeutics
CRSP
Mkt Cap5.25B
CRISPR Therapeutics AG focuses on the development of gene-based medicines, including therapies for genetic diseases, competing in the same innovative healthcare space as Quince.
Editas Medicine
EDIT
Mkt Cap500.29M
Editas Medicine, Inc. works on editing genes to treat genetic diseases, directly competing with Quince's approach to addressing genetic disorders.
Intellia Therapeutics
NTLA
Mkt Cap1.99B
Intellia Therapeutics, Inc. is a leading developer of CRISPR/Cas9 gene-editing therapies for genetic diseases, making it a direct competitor in the genetic medicine field.
Voyager Therapeutics
VYGR
Mkt Cap207.85M
Voyager Therapeutics, Inc. specializes in the development of gene therapies for neurodegenerative diseases, competing in the broader market of genetic disorder treatments.
Protagonist Therapeutics
PTGX
Mkt Cap8.45B
Protagonist Therapeutics, Inc. is engaged in the discovery and development of novel peptide-based drugs, which could compete with Quince's therapeutic approaches in a broader sense.
Fate Therapeutics
FATE
Mkt Cap361.33M
Fate Therapeutics, Inc. is involved in the development of programmed cellular immunotherapies for cancer and immune disorders, competing in the innovative treatment space.
Regenxbio
RGNX
Mkt Cap721.18M
REGENXBIO Inc. focuses on the development, commercialization, and licensing of recombinant adeno-associated virus (AAV) gene therapy, which competes with Quince's focus on regenerative medicine and genetic therapies.

About

Quince Therapeutics, Inc. (QNCX) operates as a biopharmaceutical firm dedicated to developing targeted treatments for debilitating and rare diseases. A cornerstone of their innovation is an extensive bone-targeting drug delivery platform, engineered to accurately transport diverse therapeutic agents, such as small molecules, peptides, and large molecules, directly to affected bone areas like fractures and disease sites. Leading their pipeline is NOV004, an anabolic peptide meticulously designed to pinpoint and accumulate its therapeutic action precisely at bone fracture locations. The company, previously known as Cortexyme, Inc., officially rebranded as Quince Therapeutics, Inc. in August 2022. Established in 2012, Quince Therapeutics is headquartered in South San Francisco, California.
Show more...
CEO
Dr. Dirk Thye M.D.
Employees
38
Country
United States
ISIN
US22053A3059

Listings

XNAS
US
QNCX
BOATS
BOATS
QNCX.BOATS

0 Comments

Share your thoughts

FAQ

What is Quince Therapeutics stock price today?▼
The current price of QNCX is $18.88 USD — it has increased by +1.12% in the past 24 hours. Watch Quince Therapeutics stock price performance more closely on the chart.
What is Quince Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Quince Therapeutics stocks are traded under the ticker QNCX.
Is Quince Therapeutics stock price growing?▼
QNCX stock has risen by +7.64% compared to the previous week, the month change is a -0.11% fall, over the last year Quince Therapeutics has showed a -95.01% decrease.
What is Quince Therapeutics market cap?▼
Today Quince Therapeutics has the market capitalization of 18.46M
When is the next Quince Therapeutics earnings date?▼
Quince Therapeutics is going to release the next earnings report on August 11, 2026.
What were Quince Therapeutics earnings last quarter?▼
QNCX earnings for the last quarter are 76.88 USD per share, whereas the estimation was -26 USD resulting in a +395.67% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Quince Therapeutics revenue for the last year?▼
Quince Therapeutics revenue for the last year amounts to 0 USD.
What is Quince Therapeutics net income for the last year?▼
QNCX net income for the last year is -83.98M USD.
How many employees does Quince Therapeutics have?▼
As of July 18, 2026, the company has 38 employees.
In which sector is Quince Therapeutics located?▼
Quince Therapeutics operates in the Health & Wellness sector.
When did Quince Therapeutics complete a stock split?▼
The last stock split for Quince Therapeutics was on June 30, 2026 with a ratio of 1:20.
Where is Quince Therapeutics headquartered?▼
Quince Therapeutics is headquartered in South San Francisco, United States.